↓ Skip to main content

Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model

Overview of attention for article published in Alzheimer's Research & Therapy, May 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news
4 news outlets
blogs
2 blogs
twitter
16 tweeters
facebook
3 Facebook pages

Citations

dimensions_citation
60 Dimensions

Readers on

mendeley
84 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Brivaracetam, but not ethosuximide, reverses memory impairments in an Alzheimer’s disease mouse model
Published in
Alzheimer's Research & Therapy, May 2015
DOI 10.1186/s13195-015-0110-9
Pubmed ID
Authors

Haakon B Nygaard, Adam C Kaufman, Tomoko Sekine-Konno, Linda L Huh, Hilary Going, Samantha J Feldman, Mikhail A Kostylev, Stephen M Strittmatter

Abstract

Recent studies have shown that several strains of transgenic Alzheimer's disease (AD) mice overexpressing the amyloid precursor protein (APP) have cortical hyperexcitability, and their results have suggested that this aberrant network activity may be a mechanism by which amyloid-β (Aβ) causes more widespread neuronal dysfunction. Specific anticonvulsant therapy reverses memory impairments in various transgenic mouse strains, but it is not known whether reduction of epileptiform activity might serve as a surrogate marker of drug efficacy for memory improvement in AD mouse models. Transgenic AD mice (APP/PS1 and 3xTg-AD) were chronically implanted with dural electroencephalography electrodes, and epileptiform activity was correlated with spatial memory function and transgene-specific pathology. The antiepileptic drugs ethosuximide and brivaracetam were tested for their ability to suppress epileptiform activity and to reverse memory impairments and synapse loss in APP/PS1 mice. We report that in two transgenic mouse models of AD (APP/PS1 and 3xTg-AD), the presence of spike-wave discharges (SWDs) correlated with impairments in spatial memory. Both ethosuximide and brivaracetam reduce mouse SWDs, but only brivaracetam reverses memory impairments in APP/PS1 mice. Our data confirm an intriguing therapeutic role of anticonvulsant drugs targeting synaptic vesicle protein 2A across AD mouse models. Chronic ethosuximide dosing did not reverse spatial memory impairments in APP/PS1 mice, despite reduction of SWDs. Our data indicate that SWDs are not a reliable surrogate marker of appropriate target engagement for reversal of memory dysfunction in APP/PS1 mice.

Twitter Demographics

The data shown below were collected from the profiles of 16 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 2%
Unknown 82 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 22 26%
Researcher 14 17%
Student > Master 11 13%
Student > Doctoral Student 5 6%
Other 5 6%
Other 14 17%
Unknown 13 15%
Readers by discipline Count As %
Neuroscience 27 32%
Agricultural and Biological Sciences 12 14%
Medicine and Dentistry 9 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Engineering 3 4%
Other 9 11%
Unknown 19 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 55. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 May 2017.
All research outputs
#583,351
of 21,039,170 outputs
Outputs from Alzheimer's Research & Therapy
#60
of 1,085 outputs
Outputs of similar age
#8,212
of 244,510 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 21,039,170 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,085 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.2. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,510 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them